<DOC>
	<DOCNO>NCT01975701</DOCNO>
	<brief_summary>This open-label non-randomized , multicenter , phase II study BGJ398 administer adult patient histologically confirm GBM and/or glioma subtypes FGFR1-TACC1 , FGFR3-TACC3 fusion and/or activate mutation FGFR1 , 2 3 .</brief_summary>
	<brief_title>A Phase 2 Study BGJ398 Patients With Recurrent GBM</brief_title>
	<detailed_description>Patients enrol two group . Group 1 enroll patient candidate surgery . Group 2 enroll patient surgical candidate . Patients group evaluate tumor response progression MRI every 8 week disease progression discontinuation study use RANO criterion .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients histologically confirm GBM and/or glioma subtypes time diagnosis prior relapse . 2 . Written documentation local central laboratory determination amplification translocation FGFR1TACC1 , FGFR3TACC3 fusion and/or activate mutation FGFR1 , FGFR2 , FGFR3 3 . RANO define tumor progression MRI comparison prior scan 4 . Patients must receive prior external beam radiotherapy temozolomide . Exclusion criterion : 1 . History another primary malignancy 2 . Prior current treatment FGFR inhibitor 3 . Neurological symptom relate underlying disease require increase dos corticosteroid 4 . Patients must take Enzyme Inducing AntiEpileptic Drug ( EIAED ) . If previously EIAED , patient must least two week prior study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>BGJ398 ,</keyword>
	<keyword>recurrent glioblastoma '</keyword>
	<keyword>recurrent GBM ,</keyword>
	<keyword>FGFR ,</keyword>
</DOC>